KPV 10mg – Tripeptide from inflammation research
KPV is a naturally occurring tripeptide corresponding to the C-terminal fragment (positions 11–13) of the alpha-MSH molecule. First described by Hiltz and Lipton in 1989, it is among the best-studied melanocortin receptor-independent peptide fragments with anti-inflammatory properties in preclinical research.
This 10mg vial is suitable for research approaches related to cellular inflammatory signaling pathways, intestinal barrier models and tripeptide transport mechanisms.
Mechanism of action
Unlike the complete alpha-MSH molecule, KPV does not bind to melanocortin receptors—the necessary nuclear sequence (His-Phe-Arg-Trp) is completely absent in the tripeptide. Instead, KPV is taken up in the intestinal epithelium via the di-/tripeptide transporter PepT1 and inhibits intracellular NF-κB and MAPK signaling pathways, among other things by stabilizing IκB-α and blocking the p65/RelA nuclear translocation.
Technical specifications
| Characteristic | Details |
|---|---|
| Product name | KPV (Lys-Pro-Val) |
| CAS number | 67727-97-3 |
| Crowd | 10mg |
| form | Lyophilized powder |
| sequence | H-Lys-Pro-Val-OH |
| molecular formula | C₁₆H₃₀N₄O₄ |
| Molecular weight | 342.44 g/mol |
| purity | ≥98.9 % (HPLC) |
| analysis | HPLC / LC-MS |
| storage | 2–8 °C |
Storage: Store at -20 °C (long-term); after reconstitution at 4 °C, use promptly. Protect from light and moisture.
Source: Hiltz ME, Lipton JM, „Anti-inflammatory activity of a COOH-terminal fragment of the neuropeptide α-MSH,“ FASEB Journal, 1989; Dalmasso G et al., „PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation,“ Gastroenterology, 2008
Disclaimer: Not intended for human or veterinary use. For laboratory research purposes only. Not for diagnostic or therapeutic purposes.
Reconstitution: Example calculation
For a working concentration of 10 mg/ml, the 10 mg vial is reconstituted with 1 ml of sterile bacteriostatic water (BAC water). Slowly inject the water along the inside of the vial and gently swirl it instead of shaking.
Frequently Asked Questions
Does KPV act via the melanocortin receptor?
No — unlike many alpha-MSH fragments, KPV shows anti-inflammatory effects in preclinical research independent of melanocortin receptor binding.
Since when has KPV been researched?
KPV was first described by Hiltz and Lipton in 1989 and has since been one of the best documented alpha-MSH fragments in inflammation research.
Quality assurance
Each production batch undergoes independent dual testing: HPLC analysis to determine purity and LC-MS analysis to definitively verify molecular mass and correct peptide sequence. Only after passing this test is a batch released.
Selcuk S. ✓ Verified order –
Excellent price. Fast delivery.